Physician profile
Suzanne Berkman
NPI 1235388828
$9,541.56
in general payments reported to CMS, 2019-2025
38 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,670 · 2020: $815 · 2021: $1,085 · 2022: $1,435 · 2023: $1,623 · 2024: $1,582 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,438 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,437.66 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,403.21 | 2019-2025 | |
| Abbvie INC. | $997.01 | 2019-2025 | Skyrizi, Botox, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $942.20 | 2019-2025 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $667.20 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Sun Pharmaceutical Industries INC. | $598.80 | 2019-2025 | Winlevi |
| Lilly USA, LLC | $557.10 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Galderma Laboratories, L.P. | $544.61 | 2019-2025 | Aklief, Epsolay, Oracea |
| Amgen INC. | $462.87 | 2020-2025 | Otezla, Otezla |
| Leo Pharma INC. | $334.15 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $314.09 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $280.51 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $242.84 | 2019-2025 | Cabtreo, Jublia, Arazlo |
| Incyte Corporation | $227.52 | 2021-2025 | Opzelura |
| Almirall LLC | $198.46 | 2019-2022 | |
| Ucb, INC. | $189.51 | 2021-2025 | Bimzelx, Cimzia |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $162.87 | 2019-2022 | |
| Celgene Corporation | $154.89 | 2019 | |
| Epi Health, LLC | $150.48 | 2019-2022 | |
| Allergan, INC. | $136.54 | 2019-2022 | |
| Glenmark Therapeutics INC. | $132.00 | 2019 | |
| Arcutis Biotherapeutics, INC. | $122.47 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $116.95 | 2022-2024 | Sotyktu |
| Vyne Pharmaceuticals INC. | $109.55 | 2020-2021 | |
| Dermavant Sciences, INC. | $82.01 | 2023 | Vtama |
| Sanofi-Aventis U.S. LLC | $75.09 | 2019 | |
| Journey Medical Corporation | $65.36 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.88 | 2024-2025 | Spevigo |
| Nabriva Therapeutics, Plc | $38.17 | 2020-2021 | |
| Krystal Biotech INC | $29.49 | 2023 | Vyjuvek |
| Organon LLC | $28.57 | 2025 | Vtama |
| Dermira, INC. | $19.28 | 2020 | |
| Merz North America, INC. | $17.37 | 2019 | |
| Sandoz INC. | $16.79 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $15.41 | 2020 | |
| Encore Dermatology INC. | $15.12 | 2019 | |
| Aclaris Therapeutics, INC. | $14.88 | 2019 | |
| Mission Pharmacal Company | $14.74 | 2019 | |
| Prugen, INC. Pharmaceuticals | $14.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Berkman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.